“CRISPR & Gene Editing” — FilingIndex Search

Filter

16 of 3,901

Sort

IONSIONIS PHARMACEUTICALS INC

Healthcare · Pharmaceuticals

$12.11B-1.7%

P/E —·P/S 11.4·Mgn -30.9%·ROE -78.0%·FCF -2.6%

F 3

Red 8-K

RVTYREVVITY, INC.🔥

Healthcare · Diagnostics & Tools

$11.12B+0.0%

P/E 46.1·P/S 3.9·Mgn 8.4%·ROE 3.3%·FCF 4.6%

—

CRSPCRISPR Therapeutics AG⚡

Healthcare · Biotechnology

$4.90B-3.2%

P/E —·P/S 1195.3·Mgn -13856.5%·ROE -30.3%·FCF -7.1%

—

Dilut.Red 8-K

TWSTTwist Bioscience Corp

Healthcare · Biotechnology

$4.74B+4.6%

P/E —·P/S 11.6·Mgn -19.8%·ROE -16.4%·FCF -1.6%

F 4

NTLAIntellia Therapeutics, Inc.⚡

Healthcare · Diagnostics & Tools

$1.69B+1.9%

P/E —·P/S 25.6·Mgn -597.0%·ROE -61.5%·FCF -23.4%

—

SRPTSarepta Therapeutics, Inc.

Healthcare · Pharmaceuticals

$1.62B+5.6%

P/E —·P/S 0.7·Mgn -32.5%·ROE -62.5%·FCF -19.0%

—

Red 8-K

ALLOAllogene Therapeutics, Inc.

Healthcare · Biotechnology

$656M-6.3%

P/E —·P/S —·Mgn —·ROE -65.3%·FCF -22.8%

—

Red 8-K

PRMEPrime Medicine, Inc.

Healthcare · Biotechnology

$501M-0.8%

P/E —·P/S 124.2·Mgn -4917.6%·ROE -166.4%·FCF -33.3%

—

Red 8-K

IPSCCentury Therapeutics, Inc.

Healthcare · Biotechnology

$406M+1.7%

P/E —·P/S —·Mgn —·ROE -6.0%·FCF -25.8%

—

Red 8-K

EDITEditas Medicine, Inc.

Healthcare · Biotechnology

$384M+1.3%

P/E —·P/S 9.9·Mgn -281.6%·ROE -586.6%·FCF -43.2%

—

Red 8-K

TRDAEntrada Therapeutics, Inc.

Healthcare · Pharmaceuticals

$251M-4.5%

P/E —·P/S 43.7·Mgn -2895.1%·ROE -47.0%·FCF -51.7%

—

Red 8-K

NKTXNkarta, Inc.

Healthcare · Pharmaceuticals

$205M-0.7%

P/E —·P/S —·Mgn —·ROE -33.3%·FCF -43.9%

—

13D

CRBUCaribou Biosciences, Inc.

Healthcare · Biotechnology

$158M-0.6%

P/E —·P/S 14.2·Mgn -1327.4%·ROE -121.2%·FCF -71.0%

—

DTILPRECISION BIOSCIENCES INC

Healthcare · Biotechnology

$157M-0.8%

P/E —·P/S 3.5·Mgn -96.7%·ROE -49.6%·FCF -41.9%

—

Red 8-K

MXCTMAXCYTE, INC.

Healthcare · Biotechnology

$120M-0.8%

P/E —·P/S 3.6·Mgn -135.1%·ROE -26.0%·FCF -30.2%

F 2

13DRed 8-K

CBUSCibus, Inc.

Materials · Chemicals

$94M-4.2%

P/E —·P/S 22.0·Mgn -6633.3%·ROE -582.2%·FCF -54.5%

—

Red 8-K

Filings · filterAll 10-K 10-Q 8-K S-1 DEF 14A SC 13D

Filings

40 shown

BPREBluerock Private Real Estate Fund

DEF 14A

Proxy statement — executive pay, board nominees, and shareholder votes.

Jun 30, 2026·18h ago

CYCUWCycurion, Inc.

DEF 14A

Proxy statement — executive pay, board nominees, and shareholder votes.

Companies above the $50M market cap · $1 pricefloor; SPAC/shells hidden by default. Fundamentals & prices via Polygon · signals from SEC EDGAR — verify on SEC.gov. Filings current to Jun 30 · prices to Jun 30.